Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000355328

Medchemexpress LLC Fatostatin (125B11) | 125256-00-0 | 98.2% | C18H18N2S | 200 MG
SDP

Catalog No. 5000355328
Encompass_Preferred

Fatostatin (125B11) is a specific inhibitor of SREBP activation that impairs the activation of SREBP-1 and SREBP-2. It binds to SCAP (SREBP cleavage-activating protein) and inhibits the ER-Golgi translocation of SREBPs. Fatostatin decreases the transcription of lipogenic genes in cells. It also possesses antitumor properties and lowers hyperglycemia in ob/ob mice.

  • Specific inhibitor of SREBP activation.
  • Impairs activation of SREBP-1 and SREBP-2.
  • Binds to SCAP and inhibits ER-Golgi translocation of SREBPs.
  • Decreases transcription of lipogenic genes in cells.
  • Possesses antitumor properties.
  • Lowers hyperglycemia in ob/ob mice.
  • Inhibits androgen-independent prostate cancer cell proliferation.
  • Inhibits insulin-induced adipogenesis of 3T3-L1 cells.
  • Reduced adiposity and ameliorated fatty liver in ob/ob mice.

Catalog No. 50-003-55328 Supplier Medchemexpress LLC Supplier No. HY14452200MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Fatostatin (125B11) is a specific inhibitor of SREBP activation that impairs the activation of SREBP-1 and SREBP-2. It binds to SCAP (SREBP cleavage-activating protein) and inhibits the ER-Golgi translocation of SREBPs. Fatostatin decreases the transcription of lipogenic genes in cells. It also possesses antitumor properties and lowers hyperglycemia in ob/ob mice.

  • Specific inhibitor of SREBP activation.
  • Impairs activation of SREBP-1 and SREBP-2.
  • Binds to SCAP and inhibits ER-Golgi translocation of SREBPs.
  • Decreases transcription of lipogenic genes in cells.
  • Possesses antitumor properties.
  • Lowers hyperglycemia in ob/ob mice.
  • Inhibits androgen-independent prostate cancer cell proliferation.
  • Inhibits insulin-induced adipogenesis of 3T3-L1 cells.
  • Reduced adiposity and ameliorated fatty liver in ob/ob mice.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.